Arribas [14], Caraco[6],Fischer[7], Bernal[4],
Khoo[8], Zou[3] |
Arribas [14],
Caraco[6],Fischer[7], Bernal[4], Khoo[8], Zou[3] |
Arribas [14], Caraco[6],Fischer[7], Bernal[4],
Khoo[8], Zou[3] |
Arribas [14],
Caraco[6],Fischer[7], Bernal[4], Khoo[8], Zou[3] |
Arribas [14], Caraco[6],Fischer[7], Bernal[4],
Khoo[8], Zou[3] |
Arribas [14],
Caraco[6],Fischer[7], Bernal[4], Khoo[8], Zou[3] |
Arribas [14], Caraco[6],Fischer[7], Bernal[4],
Khoo[8], Zou[3] |
Arribas [14],
Caraco[6],Fischer[7], Bernal[4], Khoo[8], Zou[3] |
800 mg |
800 mg |
800 mg |
800 mg |
800 mg |
800 mg |
800 mg |
800
mg |
Outcome |
Outcome |
Outcome |
No. of
participants (studies) |
No. of participants (studies) |
Effect estimate (95% CI) |
Risk of bias |
Risk of bias |
Inconsistency |
Inconsistency |
Inconsistency |
Indirectness |
Indirectness |
Imprecision |
Imprecision |
Imprecision |
A.Virology Profile
1.SARS-COV-2 RNA ERROR RATE
|
A.Virology Profile
1.SARS-COV-2 RNA ERROR RATE
|
A.Virology Profile
1.SARS-COV-2 RNA ERROR RATE
|
145
|
145
|
MD 1.71 [-0.11, 3.53]
|
Low
|
Low
|
Moderate
|
Moderate
|
Moderate
|
Not Serious
|
Not Serious
|
Serious
|
Serious
|
Serious
|
2. Time for clearance SARS-COV-2 or undetectable SARS-COV-2 in
the nasopharyngeal sample |
2. Time for clearance SARS-COV-2 or
undetectable SARS-COV-2 in the nasopharyngeal sample |
2. Time
for clearance SARS-COV-2 or undetectable SARS-COV-2 in the
nasopharyngeal sample |
775 |
775 |
OR 1.90 [0.80, 4.53] |
Low |
Low |
Moderate |
Moderate |
Moderate |
Not Serious |
Not Serious |
Serious |
Serious |
Serious |
3. Mean change in SARS-COV-2 from baseline in nasopharyngeal
sample |
3. Mean change in SARS-COV-2 from baseline in
nasopharyngeal sample |
3. Mean change in SARS-COV-2 from
baseline in nasopharyngeal sample |
4534 |
4534 |
MD -0.17 [-0.29,
-0.06] |
Low |
Low |
Mild |
Mild |
Mild |
Not Serious |
Not Serious |
Not Serious |
Not Serious |
Not Serious |
B. Mortality |
B. Mortality |
B. Mortality |
1823 |
1823 |
RR 0.48 [0.12, 1.98] |
Low |
Low |
Mild |
Mild |
Mild |
Not Serious |
Not Serious |
Serious |
Serious |
Serious |
Arribas[14], Caraco[6],Fischer[7] |
Arribas[14], Caraco[6],Fischer[7] |
Arribas[14], Caraco[6],Fischer[7] |
Arribas[14], Caraco[6],Fischer[7] |
Arribas[14], Caraco[6],Fischer[7] |
Arribas[14], Caraco[6],Fischer[7] |
Arribas[14], Caraco[6],Fischer[7] |
Arribas[14], Caraco[6],Fischer[7] |
Arribas[14], Caraco[6],Fischer[7] |
400 mg |
400 mg |
400 mg |
400 mg |
400 mg |
400 mg |
400 mg |
Outcome |
Outcome |
No. of participants
(studies) |
No. of participants (studies) |
Effect
estimate (95% CI) |
Effect estimate (95% CI) |
Effect estimate (95% CI) |
Risk of bias |
Risk of bias |
Inconsistency |
Inconsistency |
Inconsistency |
Indirectness |
Indirectness |
Imprecision |
Publication bias |
A.Virological Profile
1.SARS-COV-2 RNA ERROR RATE
|
A.Virological Profile
1.SARS-COV-2 RNA ERROR RATE
|
161
|
161
|
MD 2.57 [0.50, 4.65]
|
MD 2.57 [0.50, 4.65]
|
MD 2.57 [0.50, 4.65]
|
Low
|
Low
|
Low
|
Low
|
Low
|
Not Serious
|
Not Serious
|
Serious
|
N/A
|
2. Time for clearance SARS-COV-2 or undetectable SARS-COV-2 in
the nasopharyngeal sample |
2. Time for clearance SARS-COV-2 or
undetectable SARS-COV-2 in the nasopharyngeal sample |
657 |
657 |
OD
0.81 [0.45, 1.45] |
OD 0.81 [0.45, 1.45] |
OD 0.81 [0.45,
1.45] |
Low |
Low |
Mild |
Mild |
Mild |
Not Serious |
Not Serious |
Serious |
N/A |
3. Mean change in SARS-COV-2 from baseline in nasopharyngeal
sample |
3. Mean change in SARS-COV-2 from baseline in
nasopharyngeal sample |
466 |
466 |
MD -0.28 [-0.49, -0.07] |
MD
-0.28 [-0.49, -0.07] |
MD -0.28 [-0.49, -0.07] |
Low |
Low |
Low |
Low |
Low |
Not Serious |
Not Serious |
Not Serious |
N/A |
B. Mortality |
B. Mortality |
423 |
423 |
RR 0.17
[0.07, 0.43] |
RR 0.17 [0.07, 0.43] |
RR 0.17 [0.07, 0.43] |
Low |
Low |
Low |
Low |
Low |
Not Serious |
Not Serious |
Serious |
N/A |